.png){kind=icon}
.png){kind=icon}
Return
S3 guideline: Diagnosis and treatment of epidermal necrolysis(Stevens-Johnson syndrome and toxic epidermal necrolysis) -Part 2: Supportive therapy of EN in the acute and post-acute stages
.png){kind=icon}
OA
AI
DOI：10.1111/ddg.15516_g.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and of patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and practices, as well as other medical specialties involved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. The second part is concerned with the topics of supportive therapy in the acute phase of EN and outpatient follow-up treatment.
Keywords:
Drug reaction
epidermal necrolysis
Lyell syndrome
Stevens-Johnson syndrome
toxic epidermal necrolysis
Drug reaction
epidermal necrolysis
Lyell syndrome
Stevens-Johnson syndrome
toxic epidermal necrolysis
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
3.8
Papers:
4.1K
Citations:
4.3K
Organization
View more organizations